Intratympanic Injection for Autoimmune Inner Ear Disease

Overview

The investigators plan to conduct an open-label intratympanic injection proof-of-concept trial of golimumab, a TNF-alpha inhibitor, assessing for hearing loss progression in patients with autoimmune inner ear disease (AIED). This specific aim will be achieved using a two-arm approach. First, the investigators propose to dose 3 individual subjects with a single intratympanic injection of golimumab and follow each for 30 days, closely examining them for adverse events. If there are no serious adverse events, with FDA approval, the investigators propose to dose 14 subjects, each with 4 intratympanic injections of golimumab.

Full Title of Study: “Safety and Efficacy of Intratympanically Delivered Golimumab for Stabilization of Hearing in Patients With Autoimmune Inner Ear Disease: An Open-label Proof-of-concept Clinical Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 2013

Interventions

  • Drug: Golimumab
    • Intratympanic injection 0.3ml First Arm: 1 injection Second Arm: 4 injections

Arms, Groups and Cohorts

  • Experimental: First Arm
    • Determine safety of intratympanic injection
  • Experimental: Second Arm
    • Efficacy evaluation of 4 intratympanic injections

Clinical Trial Outcome Measures

Primary Measures

  • Serious Adverse Events
    • Time Frame: 30 days
    • Serious Adverse Events
  • Pure-tone threshold change
    • Time Frame: 6 weeks
    • Change in pure-tone threshold from baseline to 6 week after initiation of treatment

Participating in This Clinical Trial

Inclusion Criteria

  • Diagnosis of autoimmune inner ear disease (AIED) by the principal investigator – Idiopathic, bilateral sensorineural hearing loss – History of, or audiograms showing, rapid progression of hearing loss – Bilateral loss of at least 30 dB in one or more frequencies (0.25 – 6 kHz) – Hearing responsive on high-dose oral steroids and steroid-dependent, as determined by history and the principal investigator. The subject can be taking oral steroid, at the maintenance level, if enrolled in the First Arm and, if enrolled in the Second Arm, will begin taper after the first injection. – Provided written informed consent for participation in the clinical study Exclusion Criteria:

  • Positive MRI for vestibular schwannoma – Positive FTA (syphilis) – Significant middle ear disease (e.g., otitis media) – Positive blood test for Lyme disease – Positive tuberculosis test – Concurrent or past treatment or use of medications and/or substances known to cause ototoxicity(for example, aminoglycosides [e.g., gentamicin], cisplatin, loop diuretics, Yorgason et al., 2006) – Known adverse reaction to golimumab, adalimumab, etanercept, infliximab, rituximab, ustekinumab, or other biologic immunomodulators – Concurrent (within the past 3 months prior to enrollment) live viral intranasal vaccine (flu) – Positive test for HIV – Positive test for Hepatitis B and C – Presence of a demyelinating disease, such as multiple sclerosis – Women of childbearing potential only: Positive serum pregnancy test prior to the only/first injection – Active infections

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • House Research Institute
  • Collaborator
    • Janssen Services, LLC
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Jennifer Derebery, MD, Principal Investigator, House Research Institute

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.